Improved overall survival was seen with methylated MGMT (HR = 0.38, 95% CI 0.26–0.56, p ≤ 0.001) and non-measurable contrast-enhancing residual tumour (compared with biopsy) (HR = 0.53, 95% CI 0.32–0.87, p = 0.01). Here, MGMT is linked to neoplasm.